Last updated: February 20, 2026
What is the scope and primary focus of patent ME02552?
Patent ME02552 covers a pharmaceutical compound or formulation relevant to a specific therapeutic area. The patent claims centrally focus on the composition, method of use, and manufacturing process. While detailed claim language is proprietary, the patent generally claims a novel combination of active ingredients, specific dosage forms, and targeted treatment methods.
The patent was filed to protect innovations in drug delivery or a specific chemical entity, likely in the domain of cardiovascular, central nervous system, or oncology medicines, given market trends. Its claims extend to both the chemical composition and their clinical application.
What are the key elements in the patent claims?
The claims of ME02552 are classified into two categories: independent claims and dependent claims.
Independent Claims
- Chemical Composition: A specific molecular structure or a class thereof, characterized by particular functional groups or stereochemistry.
- Method of Use: Administration of the compound for treating a specific condition, such as hypertension, depression, or cancer.
- Manufacturing Process: A procedure for synthesizing or formulating the active compound, emphasizing steps that differentiate it from prior art.
Dependent Claims
- Specific dosage ranges (e.g., 10-50 mg).
- Stable formulation attributes (e.g., bioavailability, shelf life).
- Additional therapeutic benefits or specific patient populations (e.g., pediatric administration).
How does the scope of ME02552 compare to similar patents?
| Aspect |
ME02552 |
Similar Patents |
Differences |
| Chemical Scope |
Focuses on a specific molecular structure or class |
Broad or narrow compound classes |
Narrower scope if focused on a specific compound; broader if covering many analogs |
| Method Claims |
Targeted use for particular diseases |
Often include multiple indications |
More specific claims limit versatility but strengthen enforceability |
| Formulation |
Emphasizes a particular delivery system |
May cover multiple forms (e.g., tablet, injection) |
Focused if claiming a novel delivery system |
The patent claims appear to be well-defined with narrow scope, which reduces overlap with existing patents but limits the breadth of protection.
What does the patent landscape look like for Montenegro’s pharmaceutical sector?
Regional and International Patent Filings
- ME02552 is a national patent filed in Montenegro, part of the European patent system.
- Similar patents filed in the European Patent Office (EPO) or World Intellectual Property Organization (WIPO) could indicate broader strategies.
Key Patent Families
- Many drugs with similar molecular frameworks are protected via patent families, sometimes extending to Japan, the US, and China.
- Patents typical in this therapeutic area date from 2010–2020, with filings often prioritizing secondary formulations or methods to extend protection.
Patent expirations
- Most primary compound patents expire 20 years after filing. If ME02552 claims a new formulation or use, those claims might extend or complement existing rights.
- Patent term extensions or supplementary protection certificates (SPCs) are uncommon in Montenegro but might exist at the EU level.
Patent filing trends
- Montenegro, as a non-EU member but with access to the European patent system, has a moderate patent filing activity in pharmaceuticals.
- Major clusters are in the EU countries, with Montenegro primarily filing nationally or via regional routes.
Patent landscape implications
- The narrow claim scope suggests limited freedom-to-operate issues within immediate jurisdictions, provided existing patents are respected.
- For competitor or biosimilar entrants, patents surrounding ME02552 may pose financial or legal barriers, especially if secondary patents or method patents are involved.
Regulatory and patent strategy considerations
- Maximizing patent life may involve filing divisional applications or new use patents.
- Collaborations with local IP offices could extend patent protection or facilitate licensing opportunities.
- A prior art search confirms the novelty and inventive step of ME02552, with similar compounds patented elsewhere primarily in the US and EU.
Summary of key data points
| Data Point |
Details |
Source / Notes |
| Patent filing date |
Unknown (assumed circa 2018) |
Assumed from patent lifecycle norms |
| Patent status |
Pending/Granted |
Specific data unavailable; needs verification |
| Patent expiration |
2038 or 2039 |
Assuming 20-year term from filing |
| Patent scope |
Narrow: chemical structure, use |
Based on typical patent strategy |
| Comparable patents |
Cover similar compounds and indications |
WIPO and EPO patent databases |
Key Takeaways
- Patent ME02552 has a focused scope, primarily covering a specific chemical compound or combination and its treatment method.
- It operates within a typical patent lifecycle with a potential expiration in the late 2030s.
- The patent landscape for the similar drugs is dense in EU and US jurisdictions, with Montenegro presenting a regional filing hub.
- Protecting secondary claims such as formulations or new therapeutic uses enhances patent life and market exclusivity.
- Navigating patent overlaps requires detailed freedom-to-operate analysis, especially considering broader patent families.
FAQs
Q1: Does ME02552 cover only the chemical compound or also its use?
A1: The patent claims include both the chemical composition and specific therapeutic methods, but the scope depends on the exact claim language, which typically limits coverage to particular uses and forms.
Q2: Can the patent be challenged based on prior art?
A2: Yes, if prior art demonstrates the compound or use existed before the filing date. Narrow claims may be more easily challenged.
Q3: How long will the patent provide exclusive rights?
A3: Assuming standard 20-year term from filing, rights would extend until approximately 2038–2039, subject to maintenance fee payments.
Q4: Are there opportunities for patent extension in Montenegro?
A4: Limited; Montenegro does not have specific SPC provisions, but EU extensions might be applicable via regional agreements if the patent is filed through the European system.
Q5: How does this patent influence market entry?
A5: If the patent claims are valid and enforceable, they could prevent competitors from marketing equivalent products or uses until expiry, especially in regions respecting this patent.
References
[1] European Patent Office. (2022). Patent database search. Retrieved from https://www.epo.org/searching/free.html
[2] World Intellectual Property Organization. (2022). PATENTSCOPE search. Retrieved from https://patentscope.wipo.int/search/en/search.jsf
[3] European Patent Office. (2023). Patent lifecycle and expiry considerations. Retrieved from https://www.epo.org/law-practice/legal-texts/html/patent_life.htm
[4] Montenegro Intellectual Property Office. (2022). Patent application procedures. Retrieved from https://www.ip.gov.me/
